Blueprint Medicines Corporation provided revenue guidance for 2022. Blueprint Medicines anticipates approximately $180 million to $200 million in total revenues in 2022, including approximately $115 million to $130 million in AYVAKIT net product revenues.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
108.3 USD | -0.40% | +1.25% | +17.45% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.45% | 6.81B | |
+23.37% | 46.71B | |
+48.83% | 41.8B | |
-0.94% | 41.52B | |
-5.86% | 29.55B | |
+11.29% | 25.78B | |
-20.92% | 19.26B | |
+3.20% | 12.14B | |
-2.67% | 12.08B | |
+30.23% | 11.98B |
- Stock Market
- Equities
- BPMC Stock
- News Blueprint Medicines Corporation
- Blueprint Medicines Corporation Provides Revenue Guidance for 2022